Atrium Therapeutics, Inc. (RNA) Stock Statistics & Valuation Metrics

Atrium Therapeutics, Inc. has a market cap or net worth of $230.07M. The enterprise value is -$51.69M.

Atrium Therapeutics, Inc. has 17,105,642 shares outstanding. The number of shares has decreased by -2.65% in one year.

Atrium Therapeutics, Inc.’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -31.92%.

The current PE Ratio of Atrium Therapeutics, Inc. is ―. Atrium Therapeutics, Inc.’s PEG ratio is 0.00.

In the last 12 months, Atrium Therapeutics, Inc. had revenue of 18.62M and earned -76.68M in profits. Earnings per share was -4.48.

In the last 12 months, operating cash flow was -406.23M and capital expenditures -10.21M, giving a free cash flow of -416.44M billion.

Atrium Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Atrium Therapeutics, Inc. upcoming earnings date is May 14, 2026, After Close (Confirmed).

Atrium Therapeutics, Inc. as a current ratio of 6.53, with Debt / Equity ratio of 1.14%

In the past 12 months, Atrium Therapeutics, Inc. has paid -142.00K in taxes.

Atrium Therapeutics, Inc. EV to EBITDA ratio is 0.18, with an EV/FCF ratio of 0.33.

Atrium Therapeutics, Inc. has $267.85M in cash and marketable securities with $2.68M in debt, giving a net cash position of $265.17M billion.

Gross margin is 99.26%, with operating margin of -412.58%, and net profit margin of -411.88%.

The average price target for Atrium Therapeutics, Inc. is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy